Summary:
If you or a family member have advanced melanoma (skin cancer) you may want to consider the LUMINOS-102 study.
What is the purpose of LUMINOS-102?
LUMINOS-102 will explore if an investigational drug called PVSRIPO is safe and effective in people with advanced melanoma who have previously failed anti-PD-1/L1 therapies, such as KEYTRUDA® or OPDIVO®.
What is the investigational medication?
PVSRIPO is a modified version of the poliovirus vaccine, which is given to children throughout the world for the prevention of poliomyelitis (polio). These changes ensure PVSRIPO cannot cause polio but can still attack cancer cells. PVSRIPO can attach to and enter tumor cells, such as melanomas, to cause damage and activate an anti-tumor immune response to help eliminate the cancer cells.
Who can participate in LUMINOS-102?
You may be eligible to participate in the study if you:
- Are ≥ 18 years of age at the time of entry into the study
- Have been diagnosed with advanced melanoma that cannot be completely removed with surgery
- Previously received at least 6 weeks of treatment with an anti-PD-1/L1 therapy
How long is this study?
If you qualify to participate, you can receive PVSRIPO approximately every 3 or 4 weeks with or without an anti-PD-1 therapy as long as you are doing well, up to a year or more.